ScholarLens Back to search
2011•Journal of Clinical Medicine in PracticeRequires access

Clinical effect of maintenance chemotherapy by pemetrexed on advanced non-small-cell lung cancer

Yiheng Chen

Open publisher page 0 citations

Abstract

Objective To study the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer.Methods Thirty-six patients of advanced NSCLC who received gemcitabine plus cisplatin achieving disease stabilization(CR/PR/SD) were given pemetrexed maintenance(500 mg/m2 on d1 every 21 days) until progression of disease.MPFS,MST and diverse reactions were observed.Results The cycles of maintenance chemotherapy were 153.MPFS throughout the maintenance period was 4.2 months,and MST was 9.4 months.The main side effects were leucopenia and fatigue which were tolerable.Conclusion Maintenance chemotherapy with pemetrexed following initial therapy with gemcitabine or docetaxel plus cisplatin is feasible.It can extend the PFS,and shows a favorable toxicity profile.

About this research paper

What this paper is about

Objective To study the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer.Methods Thirty-six patients of advanced NSCLC who received gemcitabine plus cisplatin achieving disease stabilization(CR/PR/SD) were given pemetrexed maintenance(500 mg/m2 on d1 every 21 days) until progression of disease.MPFS,MST and diverse reactions were observed.Results The cycles of maintenance chemotherapy were 153.MPFS throughout the maintenance period was 4.2 months,and MST was 9.4 months.The main side effects were leucopenia and fatigue which were tolerable.Conclusion Maintenance chemotherapy with pemetrexed following initial therapy with gemcitabine or docetaxel plus cisplatin is feasible.It can extend the PFS,and shows a favorable toxicity profile.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer.Methods Thirty-six patients of advanced NSCLC who received gemcitabine plus cisplatin achieving disease stabilization(CR/PR/SD) were given pemetrexed maintenance(500 mg/m2 on d1 every 21 days) until progression of disease.MPFS,MST and diverse reactions were observed.Results The cycles of maintenance chemotherapy were 153.MPFS throughout the maintenance period was 4.2 months,and MST was 9.4 months.The main side effects were leucopenia and fatigue which were tolerable.Conclusion Maintenance chemotherapy with pemetrexed following initial therapy with gemcitabine or docetaxel plus cisplatin is feasible.It can extend the PFS,and shows a favorable toxicity profile.

Key concepts: Pemetrexed, Medicine, Gemcitabine, Cisplatin, Docetaxel, Maintenance therapy, Oncology, Chemotherapy

Back to paper searchBrowse research topicsOriginal source
Clinical effect of maintenance chemotherapy by pemetrexed on advanced non-small-cell lung cancer — Research Paper | ScholarLens